Kymera · pitchdeck
Kymera | IPO Presentation Deck | 49 slides
49 pages · 0 arc beats · 0 loops
Kymera | IPO Presentation Deck | 49 slides
Kymera · 2020-08 arc beats above · slides in the middle · loops below · scroll → 0 LOOPS
12468101214161820222426283032343638404244464849
Deck intelligence map
1 coverage by narrative range · generated from this deck JSON
Narrative range 49 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 49 slides 100% 49/49 slides 100% 49/49 slides · 213 hits — 0/49 slides
40.8% 20/49 slides 22.4% 11/49 slides — 0/49 slides
— 0/49 slides
Slide inventory
49 every slide · same image gating as the playbook
04
The slide uses a two-column list format with icons to highlight six core investment pillars.summarize
05
The slide uses a grid layout to display seven team members with their respective credentials and logos of past employers.other
06
The slide highlights financial stability and strong institutional backing.show_traction
07
The slide uses a side-by-side comparison layout to detail two distinct corporate partnerships.show_traction
08
The slide uses a process diagram to illustrate the mechanism of action for targeted protein degradation.present_solution
09
Uses a visual metaphor of a pie chart slice expanding to show existing modalities vs the opportunity space.present_solution
11
The slide uses a circular diagram to represent the integrated nature of the platform's capabilities.present_solution
12
The chart is a dot plot showing expression abundance across various tissues for different E3 ligases and targets, categorized by expression pattern (Ubiquitous,present_solution
13
The slide uses a navigation sidebar to show the current step in a larger process (Pegasus platform).present_solution
14
The slide uses 3D surface plots to illustrate the relationship between degrader concentration, binding affinity, and ternary complex formation, contrasting subopresent_solution
15
The slide uses a comparison table to show quantitative improvements in drug characteristics (potency, clearance, permeability, bioavailability).present_solution
16
The slide uses a combination of a strategic framework (top) and biological pathway diagrams (bottom) to justify their R&D focus.present_framework
17
The slide uses a color-coded system (blue for oncology, orange for inflammation/immunology) to distinguish therapeutic focus.plan_implementation
19
Includes a diagram showing the mechanism of action for an IRAK4 degrader versus a kinase inhibitor.present_solution
20
Includes a dose-response curve and a volcano plot showing high selectivity.present_solution
21
Data shows lower IC50 values for KT-474, indicating higher potency.present_solution
22
The slide uses a heatmap to visualize the reduction of phosphorylation signals, highlighting the superior performance of the degrader KT-474 compared to other ipresent_solution
23
The slide shows efficacy in a psoriasis model (ear thickness) and target engagement (IRAK4 knockdown in skin and spleen) compared to vehicle and Clobetasol.show_traction
24
The slide demonstrates a dose-dependent response of KT-474 in a disease model, linking target degradation (IRAK4) to phenotypic outcomes.show_traction
25
The charts are box plots showing IRAK4 levels relative to control. Asterisks indicate levels below the limit of quantification.show_traction
26
The slide uses a horizontal process flow to represent clinical trial stages.plan_implementation
28
The slide illustrates a biological pathway and the therapeutic intervention point for a drug candidate.present_solution
29
The slide shows a dual-axis chart comparing protein degradation percentages and cell death percentages against drug concentration.present_solution
30
Data shows dose-response curves for OCI-Ly10 and SUDHL2 cell lines.present_solution
31
The slide demonstrates efficacy of a degrader molecule in a specific cancer model.show_traction
32
The table shows IC50 values for various cell lines, highlighting significantly lower values (higher potency) for MYD88-mutant lines compared to wild-type.present_solution
33
The slide compares tumor volume over time for vehicle vs. two different doses of the lead compound across two administration routes.show_traction
34
The slide uses a timeline-style header (IND to POC) combined with a table and bulleted list of study parameters.plan_implementation
35
Abstract background imagery, likely representing biological or molecular structures.transition
36
The slide uses a biological pathway diagram to illustrate the JAK-STAT signaling mechanism.present_solution
37
The slide uses a hierarchical categorization (Cancer vs I/I Fibrosis) to map disease states to STAT3 mechanisms.establish_context
38
The slide uses volcano plots to show that STAT3 is the only protein significantly degraded, while other STAT family members remain unaffected.present_solution
39
Shows dose-response curves for STAT3 degradation, gene expression (SOCS3, MYC), and cell growth inhibition.show_traction
40
Shows two separate line charts comparing vehicle vs STAT3 degrader at various doses.show_traction
41
Includes a Western blot image showing protein levels under different treatment conditions.frame_problem
42
Includes a dose-response curve and heatmaps showing gene expression changes.present_solution
43
Includes a line chart for tumor volume and two box plots for immune cell populations (Macrophages and T cells).show_traction
44
The chart shows % incidence of disease over time (days). The STAT3 degrader at 10mg/kg and 25mg/kg, along with Dexamethasone and Normal groups, show 0% incidencshow_traction
45
The slide uses a simple timeline-like structure with a table for milestones.plan_implementation
47
The slide uses a table-based timeline format to track clinical phases (Phase 1, POB, Phase 2, POC) for specific programs.plan_implementation